摘要
他莫昔芬(Tamoxifen,TAM)为人工合成的非甾体类抗雌激素药,其通过与雌激素竞争雌激素受体,减少雌激素与受体有效结合,达到抗雌激素的效应。临床上常用于乳腺癌的预防和内分泌治疗、卵巢癌的治疗等。内分泌辅助治疗,尤其是TAM,一直运用于早期和晚期ER+乳腺癌患者的治疗。虽然治疗早期使用TAM都有明显的获益,但临床应用中发现患者容易对TAM产生耐药,并导致肿瘤进展和转移。TAM耐药依然是临床应用中面临的主要难题,其潜在的耐药机制与众多因素相关,在众多的耐药机制中是否存在有重要的关联点,有待进一步研究及发现。本文将对近年来的TAM耐药机制进行简单阐述,寻找不同耐药机制之间的关系,为乳腺癌内分泌治疗提供重要的信息。
Tamoxifen(TAM) is a synthetic non-steroidal anti-estrogenic drug. It competes with estrogen for estrogen receptors, reducing the effective binding of estrogen to receptor, to achieve antiestrogenic effects. Clinically, TAM is commonly used in the prevention and endocrine therapy of breast cancer, ovarian cancer treatment. Endocrine-assisted therapy, especially TAM, has been used in the treatment of early and late stage of ER+ breast cancer. Although the early use of TAM has significant benefits, it has been found in clinical applications that patients are easily resistant to TAM and TAM can cause tumor progression and metastasis. TAM resistance remains a major problem in clinical applications,and its potential resistance mechanism is related to many factors. Whether there are important correlation points among various resistance mechanisms needs further research and discovery. This article will briefly explain the mechanism of TAM resistance in recent years, find the relationship between different drug-resistance mechanisms, and provide important information for endocrine therapy of breast cancer.
作者
陈卓婷
陈小东
CHEN Zhuo-ting;CHEN Xiao-dong(Department of Vascular Thyroid and Breast Surgery,Affiliated Hospital of Guangdong Medical University,Zhanjiang 524002,Guangdong,CHINA)
出处
《海南医学》
CAS
2019年第6期808-811,共4页
Hainan Medical Journal
关键词
乳腺癌
他莫昔芬
耐药机制
相互关系
Breast cancer
Tamoxifen
Drug resistance mechanism
Correlation
